Effects of Foxp3⁺ T cells depletion and anti-TIGIT antibodies on tumor growth. ID8 cells (1 × 10⁶) were injected i.p. in mice expressing the DTR under the control of the Foxp3 promoter (Foxp3-DTR mice) and either 1 µg DT or PBS was injected on day 12 post-tumor implantation. The anti-TIGIT mAb (clone 1B4) (100 µg) or an isotype-matched control antibody (cIg) (Ultra-LEAF™ Purified Mouse IgG1, κ Isotype Ctrl Antibody, Catalog #401414, BioLegend, San Diego, CA) or with anti-TIGIT mAb (absolute IgG1 antibody, clone 1B4, Catalog #Ab01258, BioLegend, San Diego, CA) was given every 4 days from day 12 to day 24 post-tumor implantation. Tumor sizes are represented as means ± standard deviation, PBS + clg vs. PBS + Anti-TIGIT, p = 0.0877 on day 10, p = 0.0075 on day 15, p = 0.1078 on day 20, p = 0.0575 on day 25; PBS + clg vs. DT + clg, p = 0.0170 on day 10, p = 0.0002 on day 15, p = 0.0029 on day 20, p = 0.0004 on day 25; DT + clg vs. DT + Anti-TIGIT, p = 0.0408 on day 10, p = 0.0012 on day 15, p = 0.0009 on day 20, p < 0.0001 on day 25. Experiments have been repeated twice. statistical differences were calculated by Mann-Whitney analyses at the indicated time points